PubMed COVID-19 Clinical Care

No abstract

The governance of COVID-19 has involved the proliferation of territorial practices, through border controls designed to regulate movements not only across national and state borders, but also within cities and city regions. We argue that these urban

Cytokines are regulators of the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, the contribution of cytokine-secreting CD4^(+) and CD8^(+) memory T cells to the SARS-CoV-2-specific humoral immune

Due to the current pandemic situation, work from home, or telecommuting, has been implemented as part of public health measures to prevent the spread of SARS-CoV-2. Although this measure was introduced rapidly, it is likely to remain in effect for

Using 11 years of the U.S. Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System survey data set for 2011 to 2021, we track the evolution of depression risk for U.S. states and territories before and during the

CONCLUSION: There was a high 30-day mortality among young and middle-aged adults with severe COVID-19 in Uganda. Early recognition and targeted management of anemia and altered consciousness are needed to improve clinical outcomes.

CONCLUSIONS: The actions of the Montefiore Anesthesiology residents and fellows demonstrated that altruism and professionalism were readily available amongst physicians. Increased levels of empathy and responsibility contributed to a demonstration of

Being grateful to one's partner matters for a diverse range of interpersonal and individual well-being outcomes. However, there is little investigation on the psychological benefits of expressing gratitude to partners during the coronavirus 2019

CONCLUSION: Although MELAS is not a prevalent condition, the recent increase in the number of these patients in our center might indicate the potential role of COVID-19 in triggering the silent pre- existing mitochondrial dysfunction in these

CONCLUSIONS: The sharp reduction in costs of RSVH in infants aged 3 months outweighed the modest increase in costs observed in the 3-24 months age group. Therefore, conferring a temporal protection through passive immunisation to infants aged 3